Despite these antifibrotic treatments being available for a decade, mortality remains high, with an average survival time of only three to five years from diagnosis. There are also several side ...

As the only industry-led forum providing biopharma with the insights necessary to make strategic and scientific decisions on their fibrosis pipeline, the 6th Antifibrotic Drug Development Summit ...

Liver fibrosis is a key process in the progression of chronic liver diseases. However, there are currently no drugs ...

The same way, a compound HPH-15, has been developed by Kumamoto University, that reduces blood glucose and fat accumulation more effectively than metformin, with added benefits like antifibrotic ...

Liver fibrosis is a key process in the progression of chronic liver diseases. However, there are currently no drugs ...

Findings presented at the upcoming EASL Congress suggest that denifanstat demonstrates antifibrotic effects in patients with significant genetic risks, which may broaden its therapeutic ...

Liver fibrosis is a key process in the progression of chronic liver diseases. However, there are currently no drugs specifically designed to treat ...

Among high MeCo Score patients, antifibrotic therapy reduced the risk of recurrence by 62%, with an average follow-up period of 9.7 years after therapy. The link between breast cancer progression ...

Building on its research into immunomodulatory and antifibrotic allogeneic therapies, the biotech is running clinical development programs in acute-on-chronic liver failure (ACLF) and nonalcoholic ...